First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma.
Saved in:
| Title: | First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. |
|---|---|
| Authors: | Johnson M; Sarah Cannon Research Institute, Nashville, TN, USA., Hong D; MD Anderson Cancer Center, Houston, TX, USA., Braña I; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Schöffski P; University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium., Galvao V; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Rangwala F; Shattuck Labs, Durham, NC, 27709, USA., Ma B; Shattuck Labs, Durham, NC, 27709, USA., Hernandez R; Shattuck Labs, Durham, NC, 27709, USA., Kamat A; Shattuck Labs, Durham, NC, 27709, USA., Kato K; Shattuck Labs, Durham, NC, 27709, USA., Schreiber TH; Shattuck Labs, Durham, NC, 27709, USA., Pandite L; Shattuck Labs, Durham, NC, 27709, USA. lpandite@shattucklabs.com., Siu LL; Princess Margaret Cancer Center, Toronto, Canada. |
| Source: | Investigational new drugs [Invest New Drugs] 2025 Apr; Vol. 43 (2), pp. 284-292. Date of Electronic Publication: 2025 Mar 05. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-0646 |
|---|---|
| DOI: | 10.1007/s10637-025-01518-7 |
